Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04432090 · ClinicalTrials.gov registry record · Phase 2
GPR119 Agonist for Hypoglycemia in Type 1 Diabetes
A Phase 2 study, sponsored by AdventHealth Translational Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT04432090 is a Phase 2 study that has completed, run by AdventHealth Translational Research Institute. The registered enrollment target is 110 participants.
The verdict
NCT04432090, a Phase 2 study, has completed, sponsored by AdventHealth Translational Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
The purpose of this study is to test if a specific research medication could increase the response to low blood glucose in people with type 1 diabetes. The response of the body to low blood sugar will be measured in healthy people as a reference point.
Interventions
- DRUG Placebo
- DRUG Study Medication (MBX-2982)
- OTHER No medication for this group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2021-04-21 |
| Est. Completion | 2023-08-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04432090
The ClinicalTrials.gov registry entry for NCT04432090 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AdventHealth Translational Research Institute, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04432090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04432090 about?
NCT04432090 is a clinical study titled "GPR119 Agonist for Hypoglycemia in Type 1 Diabetes". The purpose of this study is to test if a specific research medication could increase the response to low blood glucose in people with type 1 diabetes. The response of the body to low blood sugar will be measured in healthy people as a reference point.
What is the current status of trial NCT04432090?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2021-04-21. Estimated completion is 2023-08-12.
What interventions are being tested in trial NCT04432090?
The interventions under investigation include: Placebo (DRUG), Study Medication (MBX-2982) (DRUG), No medication for this group (OTHER).
Who is sponsoring clinical trial NCT04432090?
This trial is sponsored by AdventHealth Translational Research Institute, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.